首页> 外文期刊>World journal of gastroenterology : >Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease.
【24h】

Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease.

机译:肝细胞癌和慢性肝病患者肝切除的选择标准。

获取原文
获取原文并翻译 | 示例
           

摘要

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with an annual occurrence of one million new cases. An etiologic association between HBV infection and the development of HCC has been established with a relative risk 200-fold greater than in non-infected individuals. Hepatitis C virus is also proving an important predisposing factor for this malignancy with an incidence rate of 7% at 5 years and 14% at 10 years. The prognosis depends on tumor stage and degree of liver function, which affect the tolerance to invasive treatments. Although surgical resection is generally accepted as the treatment of choice for HCC, new treatment strategies, such as local ablative therapies, transarterial embolization and liver transplantation, have been developed nowadays. With increasing detection of small HCCs from screening programs for cirrhotic patients, it is foreseen that locoregional therapy will play an important role in the near future.
机译:肝细胞癌(HCC)是全世界最常见的恶性肿瘤之一,每年发生一百万例新病例。已经建立了HBV感染与HCC发生之间的病因学关联,相对风险比未感染个体高200倍。丙型肝炎病毒也被证明是该恶性肿瘤的重要诱因,其5年发病率为7%,10年发病率为14%。预后取决于肿瘤分期和肝功能程度,这会影响对侵入性治疗的耐受性。尽管外科切除术被普遍接受为肝癌的治疗选择,但如今已经开发出新的治疗策略,例如局部消融治疗,经动脉栓塞和肝移植。随着越来越多的肝硬化患者筛查程序中对小肝癌的检测,可以预见局部治疗将在不久的将来发挥重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号